skip to content

Early Cancer Institute

 
Read more at: World View: Academic clinician–scientists risk becoming an endangered species
Stephen O’Rahilly

World View: Academic clinician–scientists risk becoming an endangered species

5 January 2024

Stephen O'Rahilly, Professor of Clinical Biochemistry and Medicine at the University of Cambridge, has highlighted his concerns about the future of the clinician–scientist in an article in Nature Medicine.


Read more at: Patient voices: Informed by research, transformed by research
Elspeth Davies, ACED PhD Student

Patient voices: Informed by research, transformed by research

1 January 2024

Elspeth Davies, a fourth year ACED PhD student in Social Anthropology, writes candidly about her experience of being diagnosed (or perhaps overdiagnosed), with an early stage melanoma, in an article published in the BMJ Evidence-Based Medicine - Patient Voices section.


Read more at: Nature Medicine paper reflects on game-changing benefits of multi-centre collaboration in achieving sample sizes for studies into less common cancers
Nature Medicine logo

Nature Medicine paper reflects on game-changing benefits of multi-centre collaboration in achieving sample sizes for studies into less common cancers

20 December 2023

The Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium was created in 2009 as a collaboration across the UK to better understand oesophageal adenocarcinoma (OAC). The aims of OCCAMS are: to develop a bioresource of samples with clinical data from patients with esophageal and gastro-oesophageal...


Read more at: East Anglia Heartburn Cancer Awareness (HCUK) at the Mill Road Winter Fair
HCUK at Mill Road Winter Fair

East Anglia Heartburn Cancer Awareness (HCUK) at the Mill Road Winter Fair

7 December 2023

A group from Early Cancer Institute and the Department of Oncology braved the weather at the Mill Road Winter Fair on Saturday 2nd December 2023 in support of Heartburn Cancer UK.


Read more at: Peter Sasieni wins 2023 Don Listwin award
Peter Sasieni

Peter Sasieni wins 2023 Don Listwin award

12 October 2023

Congratulations to Professor Peter Sasieni, Academic Director of the Kings Clinical Trials Unit at King's College London, who was presented with the 2023 Don Listwin award last night at the Early Detection of Cancer conference dinner. The award recognises outstanding contribution to cancer early detection.


Read more at: UK government proposes cigarette ban that would phase out smoking by 2040
#SmokefreeUK image

UK government proposes cigarette ban that would phase out smoking by 2040

5 October 2023

Cancer Research UK and Chief Medical Officer Chris Whitty are among many who have welcomed yesterday's (4th October) announcement of a new law to protect future generations of young people from the harms of smoking.


Read more at: Dual imaging approach generates high resolution, high dimension image dataset for whole-slide imaging
Cell Reports Methods

Dual imaging approach generates high resolution, high dimension image dataset for whole-slide imaging

27 September 2023

Combined dual-modality imaging of IF and IMC for whole-slide imaging and accurate segmentation.


Read more at: Annual Symposium 2023
Prof Xin Wei Wang

Annual Symposium 2023

15 September 2023

The Early Cancer Institute Annual Symposium took place on Thursday 14th September at the CRUK Cambridge Institute. Participants included scientists, clinicians and industry representatives from across Cambridge and further afield.


Read more at: Two new members appointed to Early Cancer Institute Scientific Advisory Board

Two new members appointed to Early Cancer Institute Scientific Advisory Board

23 August 2023

We are delighted to announce that Prof Joellen Schidkraut and Prof Dan Landau have joined the Early Cancer Institute Scientific Advisory Board (SAB).


Read more at: New breast cancer susceptibility genes identified
Nature Genetics Logo

New breast cancer susceptibility genes identified

16 August 2023

A large-scale international collaborative study has identified new genes associated with breast cancer that could eventually be included in tests to identify women at increased risk.